CAR T-Cell Therapy for Solid Tumors: Clinical Challenges and Current Advancements.
Chimeric antigen receptor (CAR T-cell) therapy has revolutionized outcomes in hematologic cancers, yet translation to solid tumors remains limited by safety and efficacy barriers.
APA
Gutierrez A, Eil R (2026). CAR T-Cell Therapy for Solid Tumors: Clinical Challenges and Current Advancements.. Surgical oncology clinics of North America, 35(2), 207-222. https://doi.org/10.1016/j.soc.2025.10.001
MLA
Gutierrez A, et al.. "CAR T-Cell Therapy for Solid Tumors: Clinical Challenges and Current Advancements.." Surgical oncology clinics of North America, vol. 35, no. 2, 2026, pp. 207-222.
PMID
41903985
Abstract
Chimeric antigen receptor (CAR T-cell) therapy has revolutionized outcomes in hematologic cancers, yet translation to solid tumors remains limited by safety and efficacy barriers. Antigen overlap between malignant and normal tissues leads to on-target, off-tumor toxicity, while the immunosuppressive tumor microenvironment restricts trafficking, persistence, and cytotoxicity. Locoregional approaches further aim to optimize delivery. This review highlights that improved antigen selection, rigorous trial design, and multidisciplinary collaboration will be required to successfully integrate CAR T-cell therapy into the care of patients with solid tumors.
MeSH Terms
Humans; Immunotherapy, Adoptive; Neoplasms; Receptors, Chimeric Antigen; T-Lymphocytes; Tumor Microenvironment; Receptors, Antigen, T-Cell